BioCentury | Sep 19, 2011
Clinical News

Revimmune cyclophosphamide regulatory update

...FDA granted Orphan Drug designation for Accentia's Revimmune cyclophosphamide to prevent graft-versus-host disease (GvHD) following bone...
...in early 2012. Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, Dec. 6, 2010). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Jul 4, 2011
Clinical News

Revimmune cyclophosphamide regulatory update

...FDA granted Orphan Drug designation for Accentia's Revimmune cyclophosphamide to treat systemic sclerosis and autoimmune hemolytic...
...Dec. 6, 2010). Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, March 5, 2007). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | May 16, 2011
Clinical News

Revimmune cyclophosphamide autoimmune data

...autoimmune diseases including multiple sclerosis (MS) and systemic lupus erythematosus (SLE) showed that 50 mg/kg/day Revimmune...
...Dec. 6, 2010). Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, March 5, 2007). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Dec 6, 2010
Company News

Accentia, Baxter deal

...indications. Accentia will use the supply to manufacture its Revimmune cyclophosphamide to treat autoimmine diseases. Revimmune...
...cyclophosphamide as part of Accentia's clinical and regulatory development of Revimmune for undisclosed autoimmune indications. Revimmune...
...were not disclosed. Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune LLC...
BioCentury | Nov 22, 2010
Company News

Accentia autoimmune, cancer news

...bankruptcy after filing in Nov. 2008. Under the plan, shareholders will retain their shares. Accentia's Revimmune...
...ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC...
BioCentury | Jun 14, 2010
Company News

Accentia autoimmune news

...this summer after which it will announce plans to start Phase III testing for its Revimmune...
...ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC...
BioCentury | Jan 28, 2008
Company News

Biovest, Revimmune deal

...Biovest received exclusive, worldwide rights to Revimmune's Revimmune cyclophosphamide to treat and prevent transplant rejection. Revimmune...
...closed at $0.50 on Jan. 18, the last trading day before the deal was announced. Revimmune...
...has exclusive, worldwide rights to Revimmune to treat autoimmune indications (see BioCentury, March 5, 2007). Revimmune...
BioCentury | Oct 15, 2007
Clinical News

Revimmune cyclophosphamide regulatory update

...ABPI received an SPA from FDA for a 1-year Phase III trial of Revimmune cyclophosphamide in...
...see BioCentury, March 5). Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Aug 6, 2007
Clinical News

Revimmune cyclophosphamide: Phase III start

...Phase III trial in 270 patients. The company licensed exclusive rights to the product from Revimmune...
...see BioCentury, March 5). Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Mar 5, 2007
Company News

Accentia, Revimmune deal

...Revimmune cyclophosphamide to treat autoimmune indications. ABPI hopes to start a Phase III study of Revimmune...
...is marketed as a generic chemotherapeutic to treat various cancers. Upon approval of the product, Revimmune...
...deal was announced. Revimmune also is eligible for royalties. Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC...
Items per page:
1 - 10 of 10
BioCentury | Sep 19, 2011
Clinical News

Revimmune cyclophosphamide regulatory update

...FDA granted Orphan Drug designation for Accentia's Revimmune cyclophosphamide to prevent graft-versus-host disease (GvHD) following bone...
...in early 2012. Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, Dec. 6, 2010). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Jul 4, 2011
Clinical News

Revimmune cyclophosphamide regulatory update

...FDA granted Orphan Drug designation for Accentia's Revimmune cyclophosphamide to treat systemic sclerosis and autoimmune hemolytic...
...Dec. 6, 2010). Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, March 5, 2007). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | May 16, 2011
Clinical News

Revimmune cyclophosphamide autoimmune data

...autoimmune diseases including multiple sclerosis (MS) and systemic lupus erythematosus (SLE) showed that 50 mg/kg/day Revimmune...
...Dec. 6, 2010). Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, March 5, 2007). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Dec 6, 2010
Company News

Accentia, Baxter deal

...indications. Accentia will use the supply to manufacture its Revimmune cyclophosphamide to treat autoimmine diseases. Revimmune...
...cyclophosphamide as part of Accentia's clinical and regulatory development of Revimmune for undisclosed autoimmune indications. Revimmune...
...were not disclosed. Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune LLC...
BioCentury | Nov 22, 2010
Company News

Accentia autoimmune, cancer news

...bankruptcy after filing in Nov. 2008. Under the plan, shareholders will retain their shares. Accentia's Revimmune...
...ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC...
BioCentury | Jun 14, 2010
Company News

Accentia autoimmune news

...this summer after which it will announce plans to start Phase III testing for its Revimmune...
...ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC...
BioCentury | Jan 28, 2008
Company News

Biovest, Revimmune deal

...Biovest received exclusive, worldwide rights to Revimmune's Revimmune cyclophosphamide to treat and prevent transplant rejection. Revimmune...
...closed at $0.50 on Jan. 18, the last trading day before the deal was announced. Revimmune...
...has exclusive, worldwide rights to Revimmune to treat autoimmune indications (see BioCentury, March 5, 2007). Revimmune...
BioCentury | Oct 15, 2007
Clinical News

Revimmune cyclophosphamide regulatory update

...ABPI received an SPA from FDA for a 1-year Phase III trial of Revimmune cyclophosphamide in...
...see BioCentury, March 5). Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Aug 6, 2007
Clinical News

Revimmune cyclophosphamide: Phase III start

...Phase III trial in 270 patients. The company licensed exclusive rights to the product from Revimmune...
...see BioCentury, March 5). Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...
BioCentury | Mar 5, 2007
Company News

Accentia, Revimmune deal

...Revimmune cyclophosphamide to treat autoimmune indications. ABPI hopes to start a Phase III study of Revimmune...
...is marketed as a generic chemotherapeutic to treat various cancers. Upon approval of the product, Revimmune...
...deal was announced. Revimmune also is eligible for royalties. Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC...
Items per page:
1 - 10 of 10